SPYH:F:F-SSgA SPDR ETFs Europe II Public Limited Company - SPDR MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 231.35

Change

-0.65 (-0.28)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.25 (-0.91%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.06 (-0.11%)

USD 109.59B
SXR8:F iShares Core S&P 500 UCITS ETF..

+0.72 (+0.13%)

USD 96.22B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.44 (-0.78%)

USD 91.00B
SXRZ:F iShares VII PLC - iShares Nikk..

-2.90 (-1.21%)

USD 54.70B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 52.21B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.44 (+0.45%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.01 (-0.13%)

USD 40.38B
0ZC:F Zscaler Inc

+2.10 (+1.37%)

USD 37.92B

ETFs Containing SPYH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.42% 77% C+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.42% 73% C 63% D
Trailing 12 Months  
Capital Gain 16.46% 65% D 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.46% 61% D- 57% F
Trailing 5 Years  
Capital Gain 56.59% 77% C+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.59% 77% C+ 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 8.53% 69% C- 67% D+
Dividend Return 8.53% 67% D+ 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.41% 73% C 91% A-
Risk Adjusted Return 101.41% 97% N/A 96% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike